The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: An analysis from the randomised, double-blind, placebo-controlled BLESS trial

The Lancet Respiratory Medicine

Volumn 2, Issue 12, 2014, Pages 988-996

  Rogers, Geraint B ^a,b   Bruce, Kenneth D ^c   Martin, Megan L ^d   Burr, Lucy D ^e   Serisier, David J ^d,e  

^a SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MATER ADULT HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; ERYTHROMYCIN ETHYLSUCCINATE; LONG ACTING DRUG; MACROLIDE; MANNITOL; PLACEBO; PREDNISOLONE; RNA 16S; SHORT ACTING DRUG; ANTIINFECTIVE AGENT; BACTERIAL RNA;

ACHROMOBACTER; ACINETOBACTER; ADULT; ARTICLE; BACTERIAL FLORA; BORDETELLA; BRONCHIECTASIS; CEREBROVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; GENE SEQUENCE; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN TISSUE; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORAXELLA; MORAXELLA CATARRHALIS; NEISSERIA; PASTEURELLA; PORPHYROMONAS; PREVOTELLA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; SPUTUM ANALYSIS; STENOTROPHOMONAS; STREPTOCOCCUS; VEILLONELLA; AGED; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; HAEMOPHILUS INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; PSEUDOMONAS INFECTIONS; SPUTUM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROMYCIN ETHYLSUCCINATE; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; LONG-TERM CARE; MALE; MICROBIOTA; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY SYSTEM; RNA, BACTERIAL; SPUTUM; YOUNG ADULT;

EID: 84919875489     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70213-9     Document Type: Article

References (38)

1. Serisier DJ, Martin M, McGuckin M, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013, 309:1260-1267.
2. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
3. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013, 309:1251-1259.
4. Kanoh S, Rubin BK Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2012, 23:590-615.
5. Howe RA, Spencer RC Macrolides for the treatment of Pseudomonas aeruginosa infections?. J Antimicrob Chemother 1997, 40:153-155.
6. Cai Y, Chai D, Wang R, Bai N, Liang BB, Liu Y Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother 2011, 66:968-978.
7. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007, 369:482-490.
8. Serisier DJ Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013, 1:262-274.
9. Serisier DJ The evidence base for non-CF bronchiectasis is finally evolving. Respirology 2014, 19:295-297.
10. Serisier DJ Macrolides for bronchiectasis and COPD-should we worry about antimicrobial resistance?. Clin Invest 2014, 4:591-594.
11. Dethlefsen L, Relman DA Incomplete recovery and individualised responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad USA 2011, 108(suppl 1):4554-4561.
12. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L Short-term antibiotics treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 2010, 5:e9836.
13. Cho I, Yamanishi S, Cox L, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012, 488:621-626.
14. Russell SL, Gold MJ, Hartmann M, et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep 2012, 13:440-447.
15. Rogers GB, van der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013, 68:731-737.
16. Rogers GB, Zain NMM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014, 11:496-503.
17. Klepac-Ceraj V, Lemon KP, Martin TR, et al. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ Microbiol 2010, 12:1293-1303.
18. Cox MJ, Allgaier M, Taylor B, et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 2010, 5:e11044.
19. Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012, 109:5809-5814.
20. Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013, 187:1118-1126.
21. DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 2006, 72:5069-5072.
22. Feizabadi MM, Majnooni A, Nomanpour B, et al. Direct detection of Pseudomonas aeruginosa from patients with healthcare associated pneumonia by real time PCR. Infect Genet Evol 2010, 10:1247-1251.
23. Nadkarni MA, Martin FE, Jacques NA, Hunter N Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 2002, 148:257-266.
24. Rogers GB, Russell LE, Preston PG, et al. Characterisation of bacteria in ascites-reporting the potential of culture-independent, molecular analysis. Eur J Clin Microbiol Infect Dis 2010, 29:533-541.
25. Bray JR, Curtis JT An ordination of upland forest communities of southern Wisconsin. Ecol Monogr 1957, 27:325-349.
26. Clarke KR Non-parametric multivariate analysis of changes in community structure. Aust J Ecol 1993, 18:117-143.
27. Matthews JNS, Altman DG Interaction 3: how to examine heterogeneity. BMJ 1996, 313:862.
28. Vrieze A, Out C, Fuentes S, et al. Impact of oral vancomycin on gut micobiota, bile acid metabolism, and insulin sensitivity. J Hepatol 2014, 60:824-831.
29. Stressman FA, Rogers GB, van der Gast CJ, et al. Long-term cultivation independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax 2012, 67:867-873.
30. Daniels TW, Rogers GB, Stressmann FA, et al. Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis. J Cyst Fibros 2013, 12:22-28.
31. Zemanick ET, Harris JK, Wagner BD, et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS One 2013, 8:e62917.
32. Slater M, Rivett DW, Williams L, et al. The impact of azithromycin therapy on airway microbiota in asthma. Thorax 2014, 69:673-674.
33. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698. for the COPD Clinical Research Network.
34. Rogers GB, Shaw D, Marsh RL, Carroll MP, Serisier DJ, Bruce KD Respiratory microbiota: addressing clinical questions, informing clinical practice. Thorax 2014, published online July 17. 10.1136/thoraxjnl-2014-205826.
35. Lyczak JB, Cannon CL, Pier GB Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002, 15:194-222.
36. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index: an international derivation and validation study. Am J Respir Crit Care Med 2013, 189:576-585.
37. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011, 121:3554-3563.
38. Thomson RM Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis 2010, 16:1576-1583.